• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
EXEL

EXEL

Exelixis, Inc.

NASDAQHealthcareBiotechnologyUS

USD52.03

+0.43 (+0.84%)

Rating:A-

Company Profile

CEO

Michael Morrissey

IPO Date

2000-04-17

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$51.97

Prev. Close

$51.60

Day Low

$51.50

Day High

$52.34

52W Low

$33.76

52W High

$52.96

Market Cap

$13.08B

Volume

0.79M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

56.9%

Avg Negative

27.2%

Avg Neutral

15.9%

News Feed

Exelixis - Takeda's Cabometyx Scores Approval In Japan For Kidney Cancer

Benzinga·8/26/2021·↑ positive

Exelixis (EXEL) Expands Oncology Collaboration With Invenra

Zacks Investment Research·8/17/2021·↑ positive

Exelixis, Invenra Expand Oncology Pact

Benzinga·8/16/2021·↑ positive

Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology

Business Wire·8/16/2021·↑ positive

Exelixis (EXEL) Beats on Q2 Earnings & Revenues, Ups Sales View

Zacks Investment Research·8/6/2021·↑ positive

Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/5/2021·↓ negative

Recap: Exelixis Q2 Earnings

Benzinga·8/5/2021·↑ positive

After Plummeting More Than 23%, Is Exelixis a Buy?

The Motley Fool·7/9/2021·↓ negative

Is Exelixis Stock a Buy After Its Disappointing Liver Cancer Study Results?

The Motley Fool·7/9/2021·↓ negative

Exelixis (EXEL) Down on Data From Ongoing Liver Cancer Study

Zacks Investment Research·6/29/2021·↓ negative